Conventional medication
PreclinicalSmall molecule
Conventional medication is one of 32 small molecule programs targeting Chronic Neck Pain. It is currently in Preclinical.
2
Indications
4
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
271 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Sudafed
KKenvue Brands
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
Flonase
TevaPhase 3
Ciclesonide HFA
Sumitomo Pharma America, Inc.Phase 3
Asmanex
NovartisPreclinical
Veramyst
GSKPreclinical
Singulair
AstraZenecaPreclinical
Xolair
RochePreclinical
Bilaxten
MMenarini International Operations Luxembourg SA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Neck Pain1 trial
Allergic Rhinitis1 trial
Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis
Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT06573164·60 enrolled
Parkinson's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Conventional medication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details